➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
AstraZeneca
Colorcon

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BIPERIDEN HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Biperiden Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00495092 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed Hospital Universitari Vall d'Hebron Research Institute Phase 2/Phase 3 2005-01-01 The aim of this study is to assess the efficacy of caffeine compared to placebo in detoxifying cocaine dependent patients. Caffeine potentiation with biperiden will be also studied. 108 with cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t.i.d.) plus biperidene (8 mg b.i.d.) or caffeine (300 - 1200 mg t.i.d.) with placebo or placebo during 6 months. Primary efficacy outcomes will be 1) patient comfort assessed with abstinence symptomatology, craving for cocaine and mental status during detoxifying period, 2) study retention and 3) cocaine use. Brain dopamine system will be assessed thru IBZM-SPECT and the apomorphine test.
NCT00495183 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status Hospital Universitari Vall d'Hebron Research Institute Phase 4 2009-01-01 The aim of this study is to assess the efficacy of caffeine compared to placebo as a maintenance treatment for cocaine dependence. Caffeine potentiation with biperiden will be also studied. Ninety patients with snorted/sniffed cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t.i.d.) plus biperidene (8 mg b.i.d.) caffeine (300 - 1200 mg t.i.d.) with placebo or placebo during 10 days in an in-hospital setting.
NCT01048138 Use of Biperiden for the Prevention of Post-traumatic Epilepsy Recruiting Cristália Produtos Químicos Farmacêuticos Ltda. Phase 3 2014-03-01 There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy.
NCT01048138 Use of Biperiden for the Prevention of Post-traumatic Epilepsy Recruiting Federal University of São Paulo Phase 3 2014-03-01 There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Biperiden Hydrochloride

Condition Name

Condition Name for Biperiden Hydrochloride
Intervention Trials
Schizophrenia 3
Cocaine Dependence 2
Schizoaffective Disorder 1
Anxiety Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Biperiden Hydrochloride
Intervention Trials
Schizophrenia 3
Cocaine-Related Disorders 3
Dementia 1
Anxiety Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Biperiden Hydrochloride

Trials by Country

Trials by Country for Biperiden Hydrochloride
Location Trials
Brazil 2
Spain 2
Taiwan 2
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Biperiden Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Biperiden Hydrochloride
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Biperiden Hydrochloride
Clinical Trial Phase Trials
Completed 3
Recruiting 3
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Biperiden Hydrochloride

Sponsor Name

Sponsor Name for Biperiden Hydrochloride
Sponsor Trials
Federal University of São Paulo 2
Hospital Universitari Vall d'Hebron Research Institute 2
Hannover Medical School 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Biperiden Hydrochloride
Sponsor Trials
Other 9
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Johnson and Johnson
Baxter
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.